#Japan #Tokyo #AI Development #Ono Pharmaceutical #Rozetta

Ono Pharmaceutical and Rozetta: Revolutionizing Document Management with AI

In an exciting collaboration, Ono Pharmaceutical Co., Ltd. and Rozetta, a leading provider of AI translation services, are joining forces to create an innovative AI tool that aims to optimize document processes in the pharmaceutical sector. This joint initiative is set to kick off in June 2025, focusing on detecting similarities and redundancies in various manuals utilized in the industry.

Objectives and Challenges

In the pharmaceutical field, regulatory changes often lead to the creation of separate manuals and procedural documents for different departments. This frequently results in numerous documents containing similar or redundant information, popularly known as “overlapping texts.” Such issues can cause confusion during operations, potential lapses in information updates, contradictions, and other risks related to the quality and compliance of operations.

The goal of this project is to tackle these document management challenges head-on by employing AI technology to automatically extract and unify these similar or duplicate texts scattered across multiple manuals. This novel approach aspires to drastically enhance the efficiency of document management in the industry.

Leveraging Rozetta's AI Technology

Rozetta, recognized for its expertise in AI translation, will utilize its generative AI capabilities and sophisticated document analysis skills to perform similarity assessments and restructured writing based on the meaning of texts, rather than simplistic full-text comparisons. This will enable a standardized and unified approach to manuals, leading to enhancements in document quality alongside significant reductions in management and operational costs.

Furthermore, the technology being developed will not be confined to a single organization; there are plans for it to be integrated into the “SOP Integration AI” as part of Rozetta's SaaS lineup, thus expanding its application as a “document optimization infrastructure” for the entire pharmaceutical industry. The aim is to contribute significantly to improving productivity across the sector, resolving individual company challenges while advancing overall industry standards.

Development Overview

This collaborative effort will involve creating AI algorithms and user interfaces (UIs) designed to automatically identify, consolidate, and restructure similar and overlapping content in multiple manuals. Such innovations are expected to streamline document organization processes, which have often relied on individual approaches, thereby enhancing overall quality and speed of operations.

Using actual manual data from Ono Pharmaceutical, the AI model’s performance will undergo rigorous validation, and based on feedback received, it will evolve into a practical prototype tailored to the needs of pharmaceutical companies. This validation-driven development will focus on underlying issues faced in real-world environments, ultimately setting the groundwork for a future SaaS product.

Timeline

• - Initiation: May 2025
• - Development Schedule:

- Late May: Requirements definition and design finalization
- June to August: Development and internal validation
- August to September: Incorporation of feedback and refinements from both Ono and Rozetta

Integration into Rakuyaku AI SaaS

The technology and user interface created during this project will not merely serve as a one-time joint development effort. There are plans to officially incorporate this capability as a core function within the Rakuyaku AI product line, ensuring that the solutions developed can be standardized and made readily available for immediate implementation across pharmaceutical companies.

Rakuyaku AI aims to evolve beyond a single-function tool, responding to the changing needs of the pharmaceutical industry with flexible and practical AI solutions. This ambitious endeavor anticipates leading the way in addressing challenges faced on the ground in the industry.

Comments from Company Leaders

Yuichi Furuya, a director at Rozetta, emphasized, “By utilizing AI not just for document creation but also for the processes of organization and integration, we aim to establish new standards for document management in the pharmaceutical industry. The manuals and SOPs are not just information assets; they are critical foundations that directly correlate with operational efficiency and quality.”

About Rakuyaku AI

The generation AI SaaS solution, "Rakuyaku AI," is designed firmly to meet the needs of pharmaceutical companies by optimizing their docs and manuals. For further information, potential clients can visit the Rakuyaku AI product site and download materials directly for a more in-depth understanding.

• - Rakuyaku AI Product Site: https://www.rozetta.jp/rakuyakuai/
• - Contact for Rakuyaku AI: https://www.rozetta.jp/rakuyakuai/inquiry/

About Rozetta

As a leading AI translation company in Japan, Rozetta provides AI services tailored toward specialized domains such as pharmaceuticals, manufacturing, and legal sectors, utilizing its extensive customer base and technological prowess. For more information about their services, visit https://www.rozetta.jp/.